Objective To review published randomised controlled trials to assess the benefit and harm of
imiquimod in the treatment of external genital warts. Data sources MEDLINE (1966 …

Our objective was to determine the optimal duration of treatment with imiquimod for external
genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts …

Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …

Objective: The purpose of this double-blind, placebo-controlled study was to evaluate the
safety, clinical efficacy and tole-rability of imiquimod (2%) in cream to cure external genital …

Genital warts are one of the most common sexually transmitted diseases worldwide. The
disease is a result of infection with low-risk types of human papillomaviruses, mostly type 6 …

The purpose of this randomized, double‐blind, placebo‐controlled study was to determine
the clinical efficacy and tolerability of an analog of imiquimod (2%) in cream to cure genital …

Background Medical therapy for genital warts remains suboptimal. The topical interferon and
cytokine inducer, imiquimod, has been proved effective for the treatment of external genital …

Objective: To investigate the efficacy and safety of imiquimod 5% cream in the treatment of
anogenital warts in a female population. Methods: In two open-label studies, female patients …

Our objective was to determine the efficacy and safety of imiquimod 5% cream in the
treatment of external genital/perianal warts in an open-label Phase IIIB trial. Patients applied …

Introduction Cutaneous warts are highly prevalent lesions caused by the infection of
keratinocytes by different types of human papillomaviruses. Although cutaneous warts are …